SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1? STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS
William Sandborn 1
1 University of California San Diego
Topic
IBD, Immunology, Paediatrics
Session
IBD Clinical II
Conference
UEG Week Virtual 2020
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]
New to myUEG?
Social Sharing